Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab

A method for eliminating a patient's need for lipoprotein apheresis therapy, or reducing the frequency of lipoprotein apheresis required by a patient to achieve a target lipoprotein level, the method comprising:

• selecting a patient with hypercholesterolemia who is being or has been treated with lipoprotein apheresis at an initial (pre-treatment) frequency, and
• administering to the patient in need thereof an antibody or antigen-binding fragment thereof that specifically binds PCSK9 comprising the heavy and light chain complementarity determining regions (CDRs) of a heavy chain variable region/light chain variable region (HCVR/LCVR) amino acid sequence pair comprising SEQ ID NOs:
• 1/6,
• wherein the antibody or antigen-binding fragment thereof that specifically binds PCSK9 is administered to the patient at a dose of about 75 mg or about 300 mg.